Apotex Company Profile
What is the competitive landscape for APOTEX
APOTEX has three hundred and sixty-five approved drugs.
There are sixteen US patents protecting APOTEX drugs. There are twenty-two tentative approvals on APOTEX drugs.
Summary for Apotex
| US Patents: | 16 |
| Tradenames: | 277 |
| Ingredients: | 265 |
| NDAs: | 365 |
| Patent Litigation for Apotex: | See patent lawsuits for Apotex |
| PTAB Cases with Apotex as petitioner: | See PTAB cases with Apotex as petitioner |
Drugs and US Patents for Apotex
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apotex Inc | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201950-001 | Sep 12, 2013 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Apotex Inc | METAPROTERENOL SULFATE | metaproterenol sulfate | SYRUP;ORAL | 075235-001 | Jan 27, 2000 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Apotex | ALENDRONATE SODIUM | alendronate sodium | TABLET;ORAL | 077982-002 | Aug 4, 2008 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Apotex | FENOFIBRATE (MICRONIZED) | fenofibrate | CAPSULE;ORAL | 202252-001 | Jul 26, 2013 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Apotex | PALIPERIDONE | paliperidone | TABLET, EXTENDED RELEASE;ORAL | 203279-001 | Jan 26, 2026 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Apotex Inc | ZOLMITRIPTAN | zolmitriptan | TABLET;ORAL | 202078-001 | May 14, 2013 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Apotex
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Apotex | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 8,101,575 | ⤷ Start Trial |
| Apotex | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 7,008,923 | ⤷ Start Trial |
| Apotex | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 6,635,618 | ⤷ Start Trial |
| Apotex | ACETADOTE | acetylcysteine | INJECTABLE;INTRAVENOUS | 021539-001 | Jan 23, 2004 | 8,148,356 | ⤷ Start Trial |
| Apotex | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 7,544,364 | ⤷ Start Trial |
| Apotex | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 7,351,691 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for APOTEX drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Transdermal System | 3.1 mg/24 hrs | ➤ Subscribe | 2015-10-09 |
| ➤ Subscribe | Extended-release Tablets | 25 mg | ➤ Subscribe | 2005-09-09 |
| ➤ Subscribe | Oral Suspension | 10 mg/5 mL | ➤ Subscribe | 2005-02-10 |
| ➤ Subscribe | Injection | 200 mg/mL, 30 mL vials | ➤ Subscribe | 2012-04-04 |
| ➤ Subscribe | Extended-release Tablets | 37.5 mg | ➤ Subscribe | 2009-05-19 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
International Patents for Apotex Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20120037025 | ⤷ Start Trial |
| Brazil | 112012000773 | ⤷ Start Trial |
| South Korea | 20140135250 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2012012640 | ⤷ Start Trial |
| Hong Kong | 1171030 | ⤷ Start Trial |
| South Korea | 20120138229 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Apotex Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2316456 | 122017000109 | Germany | ⤷ Start Trial | PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 20150326 |
| 1169038 | 132013902119320 | Italy | ⤷ Start Trial | PRODUCT NAME: DASATINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(SPRYCEL); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/06/363/001 A EU/I/06/363/015, 20061120 |
| 2487166 | PA2016038 | Lithuania | ⤷ Start Trial | PRODUCT NAME: ELVITEGRAVIRAS + KOBICISTATAS + EMTRICITABINAS + TENOFOVIRALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/15/1061 20151119 |
| 2269603 | 132015000073030 | Italy | ⤷ Start Trial | PRODUCT NAME: EVEROLIMUS O UN SUO SALE FARMACEUTICAMENTE ACCCETTABILE(AFINITOR); AUTHORISATION NUMBER(S) AND DATE(S): C(2012)5347, 20120725 |
| 1003503 | SZ 30/2006 | Austria | ⤷ Start Trial | PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN |
| 1218348 | 92154 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: AXITINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
